Adicet Bio reports Q4 2025 net loss $30.5M; Phase 1 prula-cel enrollment momentum; cash $158.5M

Adicet Bio, Inc.

Net loss Q4 2025: $30.5M ($2.94 per diluted share) compared to $28.7M ($5.06) in Q4 2024.
Full-year 2025 net loss $116.8M ($16.95 per share) vs $117.1M ($21.33) in 2024.
Cash, equivalents & investments $158.5M at Dec 31, 2025; expected to fund ops into H2 2027.
Phase 1 prula-cel autoimmune enrollment ahead; next update H1 2026; pivotal study H2 2026 subject to FDA.
ADI-212 regulatory filing for mCRPC expected Q3 2026; Phase 1 enrollment Q4 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adicet Bio, Inc. reported three months ended December 31, 2025 results: net income $30.5 million, EPS $2.94 per basic and diluted share.

Period: three months ended December 31, 2025
Net income: $30.5 million
EPS: $2.94 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2025 was $30.5 million, or a net loss of $2.94 per basic and diluted share

View on SEC.gov

Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001720580-26-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.